NADK Isoform 3 (F5E2T) Rabbit mAb #76851
- WB
To Purchase # 76851
Cat. # | Size | Qty. | Price | Ships |
---|---|---|---|---|
76851S | 100 µl | $370 | Jan 22 |
Supporting Data
REACTIVITY | H M R Mk |
SENSITIVITY | Endogenous |
MW (kDa) | 52 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
- Related Products
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Cytoplasmic NADK isoform 3 is transcribed from a unique start site compared to isoforms 1 and 2, and lacks the N-terminal, Akt-dependent, activating phosphorylation sites of Ser44, Ser46, and Ser48 found in the other isoforms (5). Cells engineered to exclusively express NADK isoform 3 exhibit constitutively increased NAD kinase activity, insensitivity to AKT agonists, and increased synthesis of NADP+ (5). NADK isoform 3 is uniquely upregulated in metastatic nodules of a PDX model of melanoma (6). Isoform 3 expression is driven by transcription factor NRF2 in response to oxidative stress, allowing melanoma cells to survive both in vitro oxidative insult and in vivo metastatic cascade by increasing NADP+ synthesis (6).
- Pollak, N. et al. (2007) J Biol Chem 282, 33562-71.
- Tedeschi, P.M. et al. (2016) Clin Cancer Res 22, 5189-5195.
- Gray, J.P. et al. (2012) Am J Physiol Endocrinol Metab 303, E191-9.
- Grose, J.H. et al. (2006) Proc Natl Acad Sci U S A 103, 7601-6.
- Hoxhaj, G. et al. (2019) Science 363, 1088-1092.
- Cascio, G. et al. (2024) Redox Biol 76, 103289.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.